Vilobelimab in combination with tocilizumab or baricitinib dramatically improves mortality in critically ill COVID-19 patients: a subgroup analysis

Subgroup analysis of vilobelimab combined with tocilizumab or baricitinib in critically ill COVID-19 patients.

Publication · 2024-11-06

More detail is on the way.

Full content is being migrated into the new site. Reach out and a senior contact will send you a copy directly.

Related services

Resource library

All white papers, case studies, publications and blogs.

Publications

Peer-reviewed and journal articles.

Contact us

Talk to a senior contact about the work behind this.